General Information of Drug (ID: DM6V0KY)

Drug Name
Xmab-2513
Synonyms XENP-0367; XENP-0522; XmAb antibodies (infusion, cancer), Xencor; Anti-CD30 humanized mAb (infusion, cancer), Xencor
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D06ALK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation antigen CD30 (TNFRSF8) TT2GM5R TNR8_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00606645) Safety Study of XmAb2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma. U.S. National Institutes of Health.
2 Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 8531.